The ARMOR study found that besifloxacin, the active molecule in BESIVANCE, demonstrated in vitro inhibitory activity against common and resistant ocular bacterial pathogens. This study measured the minimum inhibitory concentration (μg/mL) that inhibits the growth of 90% of indicated isolates (MIC90 ).
Table only includes antibiotics that are available in topical ophthalmic products that have a bacterial conjunctivitis indication. Vancomycin was part of the ARMOR study, but is not indicated for bacterial conjunctivitis. The table is not intended to demonstrate clinical efficacy.
*Adapted from Asbell PA, Sanfilippo CM, Pillar CM. US Ophthalmic Review. 2017;10(1):35-38.
†Data taken from Asbell PA, et al. JAMA Ophthalmol. 2015;133(12):1445-1455.
‡Polymyxin B is used in combination with trimethoprim for bacterial conjunctivitis.
NR = not reported.
Clinical significance of these in vitro data has not been established.